FOXA1 and breast carcinoma: Together, FOXA1 and GRHL2 induce the expression and activity of LYPD3, a Ly6 receptor family member, as well as its ligand AGR2, in mouse models of endocrine resistant breast cancer, as well as patient tumors that progressed on endocrine therapy.